Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

39.13 +1.32 (+3.49%)
Streaming Delayed Price Updated: 10:13 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Spyre Therapeutics, Inc. - Common Stock

News headline image
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.